Moderna to Present Data on mRNA Therapeutics at ICIEM 2025
ByAinvest
Tuesday, Sep 2, 2025 7:17 am ET1min read
MRNA--
The presentations, scheduled for September 2-6, 2025, in Kyoto, Japan, include three oral presentations and two poster presentations. The oral presentations will cover clinical burden data for propionic acidemia in Japan, interim data from Phase 1/2 studies for MMA and GSD1a, and final results from the dose-escalation cohorts of the mRNA-3927-P101 study for PA. The poster presentations will feature model-informed dose selection for a pivotal MMA study and interim data from the Phase 1/2 Ba1ance Study for GSD1a [2].
These presentations demonstrate Moderna's strategic expansion into rare diseases, leveraging its mRNA platform technology beyond vaccines into therapeutics. The company is addressing significant unmet medical needs with limited treatment options. The presentations will provide validation and visibility for these development programs within the scientific and medical communities specialized in metabolic disorders.
Moderna's diversification into rare diseases is a strategic move that could open up new revenue streams beyond its established COVID-19 vaccine business. While these programs are still in early to mid-stage clinical development, their advancement represents an important diversification of Moderna's pipeline.
References:
[1] https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-the-2025-international-3ddgvnfi7m8o.html
[2] https://www.newswire.com/news/moderna-announces-data-to-be-presented-at-the-2025-international-congress-of
Moderna has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism. The presentations will focus on its propionic acidemia, methylmalonic acidemia, and Glycogen Storage Disease Type 1a programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.
Moderna, Inc. (NASDAQ: MRNA) has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The presentations will focus on the company's propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a) programs, marking the first time Moderna will present data at a scientific congress for MMA and GSD1a [1].The presentations, scheduled for September 2-6, 2025, in Kyoto, Japan, include three oral presentations and two poster presentations. The oral presentations will cover clinical burden data for propionic acidemia in Japan, interim data from Phase 1/2 studies for MMA and GSD1a, and final results from the dose-escalation cohorts of the mRNA-3927-P101 study for PA. The poster presentations will feature model-informed dose selection for a pivotal MMA study and interim data from the Phase 1/2 Ba1ance Study for GSD1a [2].
These presentations demonstrate Moderna's strategic expansion into rare diseases, leveraging its mRNA platform technology beyond vaccines into therapeutics. The company is addressing significant unmet medical needs with limited treatment options. The presentations will provide validation and visibility for these development programs within the scientific and medical communities specialized in metabolic disorders.
Moderna's diversification into rare diseases is a strategic move that could open up new revenue streams beyond its established COVID-19 vaccine business. While these programs are still in early to mid-stage clinical development, their advancement represents an important diversification of Moderna's pipeline.
References:
[1] https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-the-2025-international-3ddgvnfi7m8o.html
[2] https://www.newswire.com/news/moderna-announces-data-to-be-presented-at-the-2025-international-congress-of
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet